Treatment of metastatic breast cancer
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
1. A method for the treatment of a human patient with HER2-positive metastatic breast cancer who has not received prior anti-HER2 therapy or chemotherapy for metastatic disease, comprising administering to the patient an effective amount of a combination of pertuzumab, trastuzumab, and docetaxel, wherein:
the pertuzumab is administered by intravenous infusion, at a fixed loading dose of 840 mg, followed by administration of a fixed dose of 420 mg every three weeks;
the trastuzumab is administered by intravenous infusion at a loading dose of 8 mg/kg, followed by administration of a dose of 6 mg/kg every three weeks; and
the docetaxel is administered by intravenous infusion every three weeks for at least six cycles, wherein the initial dose of docetaxel is 75 mg/m 2 and is increased to 100 mg/m 2 if the patient tolerates the initial dose.
2. A method for the treatment of a human patient with HER2-positive metastatic breast cancer who has not received prior anti-HER2 therapy or chemotherapy for metastatic disease and who has a pre-treatment left ventricular ejection fraction (LVEF) ≥50%, comprising administering to the patient an effective amount of a combination of pertuzumab, trastuzumab, and docetaxel, wherein:
the pertuzumab is administered by intravenous infusion, at a fixed loading dose of 840 mg, followed by administration of a fixed dose of 420 mg every three weeks;
the trastuzumab is administered by intravenous infusion at a loading dose of 8 mg/kg, followed by administration of a dose of 6 mg/kg every three weeks; and
the docetaxel is administered by intravenous infusion every three weeks for at least six cycles, wherein the initial dose of docetaxel is 75 mg/m 2 and is increased to 100 mg/m 2 if the patient tolerates the initial dose.